(Atlanta, December 10, 2017) — Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies. Most standard chemotherapy drugs work by killing cells in the body that are growing and dividing rapidly; this includes cancer cells, but the drugs don’t distinguish between cancer cells and normal cells. Targeted drugs, by contrast, are designed to zero in on and neutralize genetic features of cancer cells that make them different from normal cells and allow the cancer cells to grow and spread. Because they are designed to specifically target cancer cells while leaving normal cells alone, targeted therapies usually have different, and sometimes milder, adverse side effects than standard chemotherapy drugs. “These studies illustrate how better scientific understanding of what drives cancer at the molecular level is leading to novel therapies capable of keeping patients’ cancers in check for extended periods of time, while also helping them achieve better quality of life,” said press briefing moderator Laurie Sehn, MD, medical oncologist at the… Read full this story
- Illumina unveils NovaSeq X Series to accelerate genomic discoveries and improve human health
- Good Politics Versus Good Policy: The Fed’s New Average Inflation “Target”
- Precision medicine and biologics hold the key to better therapeutic outcomes in patients: Dr C N Ramchand, MagGenome
- 'Enormously exciting' prostate cancer treatment promises hope for more than 20,000 men
- Football news LIVE: Liverpool ‘target’ Enzo Fernandez as Jude Bellingham alternative, England vs Germany updates
- Loopin Promises To Make Your Meetings Productive At Last
- Is There a Way to Cure or Prevent Nightmares?
- Chennai: New technique may help prevent heart damage in breast cancer patients during radiotherapy
- What’s Next For Female Cardiovascular Health? 4 Industry Experts Weigh In
- Alzheimer's disease: How to mitigate risk factors in common form of dementia
Targeted therapies show promise improving outcomes across several hematologic malignancies have 319 words, post on www.eurekalert.org at December 10, 2017. This is cached page on Bach Thien. If you want remove this page, please contact us.